RD-140

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameRD-140
Drug Alias NameRD140IASO-140
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-GPRC5DAnti-BCMA
TargetsG-protein coupled receptor family C group 5member DB-cell maturation protein
Therapy Area/IndicationsMultiple MyelomaLeukemia, Plasma Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Iaso Biotherapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPeking University People'S HospitalNanjing Iaso Biotherapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLeukemia, Plasma Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A